ArticleBreast cancer research : BCR2000
Characterization of fibroblast growth factor receptor 2 overexpression in the human breast cancer cell line SUM-52PE.
Article in Breast cancer research : BCR, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 71 citations in OpenAlex.
- Trial
- Article
- Article
- Breast Cancer, Diabetes Mellitus and Glucagon-Like Peptide-1 Receptor Toward Exploring Their Possible Associations.Breast cancer research and treatment · 2021Article
- Is there an association between liraglutide use and female breast cancer in a real-world setting?Diabetes, metabolic syndrome and obesity : targets and therapy · 2018Article
- Association of FGFR2 and PI3KCA genetic variants with the risk of breast cancer in a Chinese population.Cancer management and research · 2018Article
- FGFR2 risk SNPs confer breast cancer risk by augmenting oestrogen responsiveness.Carcinogenesis · 2016Article
- Functional oncogene signatures guide rationally designed combination therapies to synergistically induce breast cancer cell death.Oncotarget · 2016Article
- miR-494 inhibits ovarian cancer cell proliferation and promotes apoptosis by targeting FGFR2.Oncology letters · 2016Article
- TNRC9 rs12443621 and FGFR2 rs2981582 polymorphisms and breast cancer risk.World journal of surgical oncology · 2016Article
- Inhibition of fibroblast growth factor receptor 2 attenuates proliferation and invasion of pancreatic cancer.Cancer science · 2014Article
- A study on genetic variants of Fibroblast growth factor receptor 2 (FGFR2) and the risk of breast cancer from North India.PloS one · 2014Article
- Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers.Apoptosis : an international journal on programmed cell death · 2013Review
- Comparison of genetic variation of breast cancer susceptibility genes in Chinese and German populations.European journal of human genetics : EJHG · 2013Article
- Article
- Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer.Cancer discovery · 2013Article
- The FGF/FGFR axis as a therapeutic target in breast cancer.Expert review of endocrinology & metabolism · 2013Article
- Article
- Adeno-associated viral vectors based on serotype 3b use components of the fibroblast growth factor receptor signaling complex for efficient transduction.Human gene therapy · 2012Article
- Challenges and opportunities in the targeting of fibroblast growth factor receptors in breast cancer.Breast cancer research : BCR · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The fibroblast growth factor receptor (FGFR)2 gene has been shown to be amplified in 5-10% of breast cancer patients. A breast cancer cell line developed in our laboratory, SUM-52PE, was shown to have a 12-fold amplification of the FGFR2 gene, and FGFR2 message was found to be overexpressed 40-fold in SUM-52PE cells as compared with normal human mammary epithelial (HME) cells. Both human breast cancer (HBC) cell lines and HME cells expressed two FGFR2 isoforms, whereas SUM-52PE cells overexpressed those two isoforms, as well as several unique FGFR2 polypeptides. SUM-52PE cells expressed exclusively FGFR2-IIIb isoforms, which are high-affinity receptors for fibroblast growth factor (FGF)-1 and FGF-7. Differences were identified in the expression of the extracellular Ig-like domains, acid box and carboxyl termini, and several variants not previously reported were isolated from these cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.